This project is about helping young women, age 45 and under, who are diagnosed with breast cancer. These women often have more serious types of cancer and are diagnosed later than older women. We want to make it easier for them to learn about and join clinical trials. Clinical trials are studies that test new treatments to see if they work better than current ones.We want young women with breast cancer to get clear information and strong support when making choices about their care. Many are also dealing with big life events like having children, starting careers, or handling stress. These things can make it hard to think about joining a clinical trial. By adding a research assistant and training nurses to help, we hope to make the process easier and less confusing.This program will help young women feel more confident and informed about their treatment options. It will also help them learn about new therapies through clinical trials. By giving support and easy-to-read materials in both English and Spanish, we hope to improve their care and make their experience less stressful.
Funded by Jeffrey Vinik and the Tampa Bay Lightning in support of Hockey Fights Cancer powered by the V Foundation
White blood cells in the body are responsible for fighting disease. The disease is usually infection but the immune system can also kill the tumor in a patient with cancer. There are new forms of treatment called “immunotherapy” which increase the immune response to a tumor in a patient with cancer. This proposal is based on treatment using the white blood cells that reside within a tumor. Because they live within the tumor, they recognize the tumor as foreign, but the tumor defends itself from these cells. To tip the balance in favor of the immune system, these cells are grown outside of the body, away from the harmful effects of the tumor. They are then given back to the patient and since they are stronger, they can more easily kill the tumor. An ongoing clinical trial is testing the treatment in pediatric patients. In this proposal we will evaluate the cells that are given to these patients so we can better understand how they work and improve the treatment for future patients.
Breast cancer is the most common cancer type and 2nd leading cause of death by cancer for women in the US. Patients with early-stage breast cancer or DCIS can survive. But there are groups at high risk for the cancer coming back or developing invasive breast cancer (IBC). These patients are treated with surgey, radiation, and other types of therapies. While these treatments often work, recurrence and IBC are still problems. Our project aims to create a therapy using the patients’ immune system. This therapy will help the body to recognize and engage in the fight against their cancer. If successful, this therapy will be the first non-estrogen inhibitory immunotherapy. And this therapy will help prevent the cancer from coming back and prevent IBC.
Funded with support from Hockey Fights Cancer in honor of Ben Stelter
Glioblastoma (GBM) is the deadliest adult brain cancer. Even with standard of care treatment, survival rates are low. A major challenge is that the brain’s protective barrier blocks most drugs. The tumor also weakens the immune system, making it harder for treatments to work. CAR-T cell therapy is a promising treatment that trains T cells, a special immune cell, to recognize and attack cancer cells. It works well in other cancers, but not GBM. Normally, T cells follow signals from proteins called chemokines and cytokines to locate and fight disease. However, GBM blocks these signals, stopping T cells from working properly. Our study will develop a new immune gene therapy using a harmless virus called AAV to help the immune system fight GBM. This therapy reprograms nearby brain cells (called astrocytes) to send signals that attract and activate immune cells, including CAR-T cells. Our gene therapy will deliver two key proteins: CXCL9 (which attracts T cells) and IL-2 (which helps them grow and stay active). This targeted approach ensures a steady immune response right at the tumor. We will combine this immune gene therapy with CAR-T cells to improve their ability to find, survive, and attack the tumor. Our research will study how AAV works in the brain, activates CAR-T cells, and which AAVs can be used in human clinical trials.
Funded by the 2025 Kay Yow Cancer Fund Final Four Research Award
Ovarian cancer is hard to treat. Most patient’s cancer comes back after standard treatment. Once the disease is back it is more difficult to treat and patients will eventually die from it. Chemotherapy can also cause direct harm to the body. This can make patients delay treatment, stop it altogether, or lower their doses. It can also harm the good bacteria in the gut, which is important for how well treatments work. Our goal is to come up with new ways to predict, prevent, and manage these harmful effects. We also want to develop new therapies that can lead to complete and lasting responses, increasing chances of cure right from the start. To reach this goal we will use mathematical modeling. This will allow us to test many treatments quickly, which cannot be done with traditional laboratory methods. First, we will use patient blood samples to predict the risk of toxicity, helping doctors know when to change or pause treatment. Next, we will use math modeling to find the best combinations of new targeted therapies. Finally, we will reduce the harmful effects of chemotherapy on the gut using math modeling to improve how well those therapies work. This research could change how we treat cancer. It may lead to complete tumor response and better chances for a cure.
Funded in partnership with the Dolphins Cancer Challenge (DCC)
Glioblastoma (GBM) is the most frequent and deadly malignant brain tumor. Escape from the body’s immune response is a critical factor that makes GBM untreatable. One promising anti-GBM strategy is to augment the tumor-fighting capacity of immune cells. CD8+ T cells have the potential to kill tumors, but cancers make them not function properly. Strategies that aim to prevent this process have not been successful in GBM yet. We recently found that a molecule named dipeptidyl peptidase 4 (DPP-4) is present on dysfunctional T cells at high levels. Furthermore, we observed that DPP-4 prevents CD8+ T cells from killing tumors. In this application, we aim to determine how DPP-4 reprograms T cells to a nonfunctional state. DPP-4 inhibitors are commonly used by patients with diabetes. We seek to repurpose these drugs in combination with existing immune-activating strategies to improve T cell response against GBM. Collectively, these studies will define DPP-4 as a new treatment target in GBM.
Funded in partnership with Miami Dolphins Foundation
Cancer immunotherapy has been one of the great advances in the treatment of cancer in the past decade. In B-cell cancers, hijacking T-cells by insbertion of a synthetic receptor (CAR-T cells) enables these cells to recognize and kill lymphoma through a specific marker (CD19). However, despite CAR-T leading to high rates of remission, only about 40% of patients are cured. Some major causes for why CAR-T does not work in patients is too great a burden of tumor cells and the cancer learning to hide the target the CAR-T needs to be effective. Therefore, there is great interest in combining CAR-T with other cancer therapies to improve efficacy. We have a clinical trial combining 2 drugs, mosunetuzumab and polatuzumab, targeting other lymphoma markers (CD20 and CD79b), together with CAR-T in patients with aggressive B-cell lymphomas. Using this approach, we hope to improve outcomes by addressing the main reasons for CAR-T failure. In this grant, we will track a patient’s response to treatment by monitoring a patient’s blood for small tumor fragments, to allow us to determine when extra therapy is needed in addition to CAR-T. We will precisely measure the amount of target markers on lymphoma cells to assess its importance for success of this therapy. Lastly, as CAR-T therapy has a high risk of infection, we will monitor recovery of the immune system to learn how adding extra therapies may affect a patient’s risk.
Funded in partnership with Miami Dolphins Foundation
Pancreatic cancer is a really bad disease that’s hard to treat. Even though treatments like immunotherapy have helped with other cancers, they haven’t worked well for pancreatic cancer. Some people get pancreatic cancer because of a problem gene passed down in their family, like BRCA. We tried treating these people with a mix of immunotherapy drugs, and it worked amazingly well for a few. Their cancer completely went away, and they stayed cancer-free for over 5 years. Now, we’re trying to figure out why it worked for some and not others. We are doing some lab experiments in mice with pancreatic cancer and it seems like something in the cancer cells called STING might be the main reason why this treatment is working. We want to study more tumors from people with pancreatic cancer and the BRCA gene problem to confirm this. Also, we plan to do more tests on mice to see if we can make STING work better in those that don’t respond to treatment at first. If these tests work, it could help create a new treatment for pancreatic cancer in the future.
Funded in partnership with Miami Dolphins Foundation
Blood cell cancers often bear mutations in STAT3. This protein is normally beneficial but, when overactive, becomes a cancer ‘driver’. More than 150 relevant mutations have been identified but only 7 have been studied in any detail. Thus, it remains unknown how mutations alter STAT3 activity to drive blood cancers. In fact, the same can be said of most oncogenes. The capacity to identify mutations far exceeds the capacity to appraise them. Our research will directly address this problem. To that end, we have devised an experimental platform that enables us to study all known STAT3 mutations at once. This platform is scalable, new mutations can be easily added, and readily adaptable to other cancer drivers. It is also designed to be implement in mice, allowing us test drugs in vivo, across all mutants at once. Using this platform, we will advance basic understanding of STAT3 and inform treatment options for associated blood cancers.
Funded in partnership with the Dolphins Cancer Challenge (DCC)
In recent years, colorectal cancer (CRC) has become the third most common and second most deadly cancer in the US. CRC is the leading cause of cancer death among Americans under 50 years old, but experts do not know why rates are increasing among young people. Moreover, we do not have a good way of detecting people who are at higher risk of CRC. These people should receive early monitoring and undergo extra measures to prevent CRC. How can we identify these at-risk individuals? We propose that certain bacteria cause the production of an enzyme (DUOX2) in the gut. High levels of this enzyme are found in people with gut inflammation and people with CRC. In the proposed research, we plan to test whether patients with different types of CRC have different levels of DUOX2. We expect that some CRC types will have higher levels than others. Next, we will try to identify the bacteria that lead to high DOUX2 levels. Discovering these bacteria may help to identify people at higher risk of CRC (people with higher amounts of these bacteria) and suggest new cancer treatments (ones targeting these bacteria). Finally, we will test whether drugs that are already approved for use in humans, along with other products of bacteria, can reduce levels of DUOX2 in the gut. Identifying these drugs may improve prevention and treatment for CRC.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.